RS55931B1 - Inhibitori proteazoma za lečenje kancera - Google Patents
Inhibitori proteazoma za lečenje kanceraInfo
- Publication number
- RS55931B1 RS55931B1 RS20170474A RSP20170474A RS55931B1 RS 55931 B1 RS55931 B1 RS 55931B1 RS 20170474 A RS20170474 A RS 20170474A RS P20170474 A RSP20170474 A RS P20170474A RS 55931 B1 RS55931 B1 RS 55931B1
- Authority
- RS
- Serbia
- Prior art keywords
- bortezomib
- administered
- cancer
- proteasome
- days
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24771409P | 2009-10-01 | 2009-10-01 | |
| PCT/EP2010/005994 WO2011038924A2 (en) | 2009-10-01 | 2010-10-01 | Treatment of disease with proteasome inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS55931B1 true RS55931B1 (sr) | 2017-09-29 |
Family
ID=43629456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20170474A RS55931B1 (sr) | 2009-10-01 | 2010-10-01 | Inhibitori proteazoma za lečenje kancera |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20110189204A1 (https=) |
| EP (1) | EP2519231B1 (https=) |
| JP (1) | JP2013506626A (https=) |
| AU (2) | AU2010300259A1 (https=) |
| CA (1) | CA2776327A1 (https=) |
| CY (1) | CY1118925T1 (https=) |
| DK (1) | DK2519231T3 (https=) |
| ES (1) | ES2624644T3 (https=) |
| HR (1) | HRP20170702T1 (https=) |
| HU (1) | HUE032571T2 (https=) |
| LT (1) | LT2519231T (https=) |
| ME (1) | ME02725B (https=) |
| PL (1) | PL2519231T3 (https=) |
| PT (1) | PT2519231T (https=) |
| RS (1) | RS55931B1 (https=) |
| SI (1) | SI2519231T1 (https=) |
| SM (1) | SMT201700231T1 (https=) |
| WO (1) | WO2011038924A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104039328B (zh) * | 2011-11-11 | 2018-10-09 | 米伦纽姆医药公司 | 对蛋白酶体抑制剂的反应的生物标记 |
| CA2966288A1 (en) * | 2014-10-30 | 2016-05-06 | Big Dna Ltd | Combination therapy |
| WO2017070328A1 (en) * | 2015-10-20 | 2017-04-27 | The Cleveland Clinic Foundation | STIMULATION OF 11β-HSD2 EXPRESSION TO IMPROVE HORMONAL THERAPY OF STEROID-DEPENDENT DISEASE |
| US11947330B2 (en) * | 2019-03-06 | 2024-04-02 | The Boeing Company | Tool orientation systems and methods |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4499802A (en) * | 1982-09-29 | 1985-02-19 | Container Graphics Corporation | Rotary cutting die with scrap ejection |
| US4537773A (en) | 1983-12-05 | 1985-08-27 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid derivatives |
| US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
| US5081110A (en) * | 1986-03-27 | 1992-01-14 | Sloan-Kettering Institute For Cancer Research | Method of killing sarcoma cells using fludarabine phosphate and ionizing radiation |
| US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| CN1339970A (zh) * | 1999-02-10 | 2002-03-13 | 鹤尾隆 | 抗癌药物增强剂 |
| JP4162491B2 (ja) * | 2001-01-25 | 2008-10-08 | アメリカ合衆国 | ボロン酸化合物製剤 |
| KR20070107707A (ko) | 2005-01-21 | 2007-11-07 | 아스텍스 테라퓨틱스 리미티드 | 피라졸 키나제 억제제와 추가 항종양제의 조합물 |
| MX2007008781A (es) | 2005-01-21 | 2007-09-11 | Astex Therapeutics Ltd | Compuestos farmaceuticos. |
| US20060193844A1 (en) * | 2005-02-28 | 2006-08-31 | Proteolix, Inc. | Methods for enzyme inhibition |
| EP1876893B1 (en) * | 2005-04-15 | 2012-04-11 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| WO2008086005A1 (en) * | 2007-01-09 | 2008-07-17 | University Of South Florida | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
| MX2010002179A (es) * | 2007-08-24 | 2010-04-27 | Stichting Het Nl Kanker I | Composicion para el tratamiento de enfermedades neoplasicas. |
-
2010
- 2010-10-01 HU HUE10807320A patent/HUE032571T2/en unknown
- 2010-10-01 AU AU2010300259A patent/AU2010300259A1/en not_active Abandoned
- 2010-10-01 SI SI201031448A patent/SI2519231T1/sl unknown
- 2010-10-01 DK DK10807320.6T patent/DK2519231T3/en active
- 2010-10-01 HR HRP20170702TT patent/HRP20170702T1/hr unknown
- 2010-10-01 LT LTEP10807320.6T patent/LT2519231T/lt unknown
- 2010-10-01 PL PL10807320T patent/PL2519231T3/pl unknown
- 2010-10-01 RS RS20170474A patent/RS55931B1/sr unknown
- 2010-10-01 JP JP2012531285A patent/JP2013506626A/ja active Pending
- 2010-10-01 SM SM20170231T patent/SMT201700231T1/it unknown
- 2010-10-01 US US12/896,289 patent/US20110189204A1/en not_active Abandoned
- 2010-10-01 ME MEP-2017-106A patent/ME02725B/me unknown
- 2010-10-01 ES ES10807320.6T patent/ES2624644T3/es active Active
- 2010-10-01 EP EP10807320.6A patent/EP2519231B1/en not_active Revoked
- 2010-10-01 CA CA2776327A patent/CA2776327A1/en not_active Abandoned
- 2010-10-01 WO PCT/EP2010/005994 patent/WO2011038924A2/en not_active Ceased
- 2010-10-01 PT PT108073206T patent/PT2519231T/pt unknown
-
2016
- 2016-12-22 AU AU2016277700A patent/AU2016277700A1/en not_active Abandoned
-
2017
- 2017-06-01 CY CY20171100580T patent/CY1118925T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010300259A1 (en) | 2012-04-26 |
| ES2624644T3 (es) | 2017-07-17 |
| PT2519231T (pt) | 2017-05-25 |
| JP2013506626A (ja) | 2013-02-28 |
| SMT201700231T1 (it) | 2017-07-18 |
| WO2011038924A9 (en) | 2011-07-14 |
| US20110189204A1 (en) | 2011-08-04 |
| SI2519231T1 (sl) | 2017-07-31 |
| EP2519231B1 (en) | 2017-03-15 |
| WO2011038924A3 (en) | 2011-05-26 |
| PL2519231T3 (pl) | 2017-09-29 |
| LT2519231T (lt) | 2017-05-10 |
| EP2519231A2 (en) | 2012-11-07 |
| DK2519231T3 (en) | 2017-06-26 |
| AU2016277700A1 (en) | 2017-02-02 |
| CY1118925T1 (el) | 2018-01-10 |
| ME02725B (me) | 2017-10-20 |
| HUE032571T2 (en) | 2017-09-28 |
| HRP20170702T1 (hr) | 2017-07-14 |
| WO2011038924A2 (en) | 2011-04-07 |
| CA2776327A1 (en) | 2011-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sahni et al. | Chemotherapy-associated renal dysfunction | |
| ES2863996T3 (es) | Terapia de combinación para el tratamiento del cáncer | |
| CA2952051C (en) | Fap-activated therapeutic agents, and uses related thereto | |
| Minocha et al. | Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors | |
| CN108383893A (zh) | 用于治疗实体瘤的fap-活化的蛋白酶体抑制剂 | |
| WO2007076055A9 (en) | Compositions and methods comprising proteinase activated receptor antagonists | |
| ES2738448T3 (es) | Terapia combinada de procaspasa para el tratamiento del cáncer | |
| WO2014207556A1 (en) | Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations | |
| JP6592097B2 (ja) | 併用療法 | |
| JP2014528409A (ja) | 増殖性疾患（がん）の治療において使用するためのＳＭＡＣ模倣体（ビリナパント（ｂｉｒｉｎａｐａｎｔ）） | |
| RS55931B1 (sr) | Inhibitori proteazoma za lečenje kancera | |
| EP3773582B1 (en) | Selective anti-cancer agent effective for prevention and treatment | |
| WO2009062135A1 (en) | Hsp90 inhibitors of protein-protein interaction hsp90 chaperone complexes and therapeutic uses thereof | |
| US20250064824A1 (en) | Administration of aurora kinase inhibitor and chemotherapeutic agents | |
| US20200397738A1 (en) | Methods for treating cancer and protecting renewable tissues | |
| CA2835631A1 (en) | Use of arsenic for cancer therapy protection | |
| AU2017217330A1 (en) | Compositions and uses thereof | |
| JP2021011453A (ja) | 抗がん剤投与により生じる皮膚障害の治療又は予防剤 | |
| KR20240028451A (ko) | Bap1 및 pbrm1 중 적어도 하나의 기능 저하를 갖는 종양에 대한 의약 조성물 및 항종양제 | |
| KR20090086977A (ko) | 골암의 치료 또는 예방을 위한 ｍｔｋｉ 1의 용도 | |
| Shapiro | CDK Inhibitors | |
| NZ715285B2 (en) | Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations |